IP Library › Granted Patent US 8,344,135
Granted Patent B2
US 8,344,135 · App. 12/675,663 · Granted Jan 1, 2013

Heterocyclic compound and use thereof

Assignee: Takeda Pharmaceutical Company Limited
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,344,135
App. No.
12/675,663
Granted
Jan 1, 2013
Kind
B2
Abstract

The present invention provides a heterocyclic compound having a strong Raf inhibitory activity, which is represented by the following formula wherein each substituent is as defined in the present specification, or a salt thereof.

Claims (45)

1. A compound represented by the formula

wherein

R 1c is

(1) C 1-6 alkyl-carbonyl optionally having 1 to 3 substituents selected from the group consisting of

(i) hydroxy,

(ii) C 1-6 alkyl-oxy,

(iii) di-C 1-6 alkylamino, and

(iv) a 5- or 6-membered nonaromatic heterocyclic group optionally having 1 or 2 substituents selected from

(a) hydroxy,

(b) halogen,

(c) C 1-6 alkyl optionally substituted by hydroxy, and

(d) C 3-8 cycloalkyl,

(2) C 2-6 alkenyl-carbonyl having substituent(s) selected from the group consisting of

(i) C 6-10 aryl optionally having 1 to 3 halogen atoms, and

(ii) a 5- or 6-membered monocyclic aromatic heterocyclic group,

(3) C 3-8 cycloalkyl-carbonyl optionally having 1 to 3 C 1-6 alkyl, or

(4) 5- or 6-membered monocyclic aromatic heterocyclyl-carbonyl

R 2c is C 6-10 aryl optionally having 1 or 2 substituents selected from the group consisting of

(1) halogen,

(2) C 3-8 cycloalkyl optionally having cyano,

(3) C 1-6 alkyl-oxy optionally having 1 to 3 substituents selected from the group consisting of halogen and cyano, and

(4) C 1-6 alkyl optionally having 1 to 3 substituents selected from the group consisting of halogen, C 2-6 alkynyl, and cyano;

R 4c is hydrogen;

X c is —O—, —NH—, or —N(CH 3 )

Y c is —NHCO— or —CONH—

Z c is —S;

Q c is ═CH—; and

ring A c is a benzene ring optionally having 1 or 2 substituents selected from the group consisting of

(1) C 1-6 alkyl optionally having 1 to 3 halogen atoms,

(2) cyano,

(3) halogen, and

(4) C 1-6 alkyl-oxy;

or a salt thereof.

2. The compound of claim 1 , wherein X c is —O—.

3. The compound of claim 1 , wherein Y c is —NHCO—.

4. 2-Chloro-3-(1-cyano-1-methylethyl)-N-[5-({2-[(cyclopropylcarbonyl)amino][1,3]thiazolo[5,4-b]pyridin-5-yl}oxy)-2-fluorophenyl]benzamide;

N-(5-{[2-(acetylamino)[1,3]thiazolo[5,4-b]pyridin-5-yl]oxy}-2-fluorophenyl)-2-chloro-3-(1-cyanocyclopropyl)benzamide;

2-chloro-3-(1-cyanocyclopropyl)-N-[5-({2-[(cyclopropylcarbonyl)amino][1,3]thiazolo[5,4-b]pyridin-5-yl}oxy)-2-fluorophenyl]benzamide;

2-chloro-3-(1-cyanocyclopropyl)-N-[5-({2-[(cyclopropylcarbonyl)amino][1,3]thiazolo[5,4-b]pyridin-5-yl}oxy)-2,4-difluorophenyl]benzamide;

2-chloro-3-(1-cyano-1-methylethoxy)-N-{5-[{2-[(cyclopropylcarbonyl)amino][1,3]thiazolo[5,4-b]pyridin-5-yl}(methy)amino]-2-fluorophenyl}benzamide;

2-chloro-3-(1-cyano-1-methylethoxy)-N-{5-[{2-[(cyclopropylcarbonyl)amino][1,3]thiazolo[5,4-b]pyridin-5-yl}(methyl)amino]-2-fluorophenyl}benzamide benzenesulfonate; or

2-chloro-3-(1-cyano-1-methylethoxy)-N-[5-({2-[(cyclopropylcarbonyl)amino][1,3]thiazolo[5,4-b]pyridin-5-yl}amino)-2-fluorophenyl]benzamide;

or a salt thereof.

5. A pharmaceutical agent comprising the compound of claim 1 or a salt thereof.

6. The compound of claim 1 , wherein Y c is —CONH—.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 26, 2010
From: HIROSE, MASAAKI; OKANIWA, MASANORI; HAYASHI, YOKO; TAKAGI, TERUFUMI
To: TAKEDA PHARMACEUTICAL COMPANY LIMITED
Reel/Frame 024003/0542 →
Priority Claims (2)
JP 2007-223284 · Aug 29, 2007 · national
JP 2008-187953 · Jul 18, 2008 · national
Continuity (1)
Related Publication 20100249119A1 · Sep 30, 2010